February 27, 2023: Adamis Pharmaceuticals announces merger with DMK Pharmaceuticals. Read the press release. Watch the video.
Adamis Pharmaceuticals logo - Click here to go back to the homepage
  • About
    • Overview
    • Management
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI® (naloxone)
  • Pipeline
    • Specialty Pharmaceuticals
    • APC-400 (tempol) – Capsule
  • Patients
  • Investors & Media
  • Careers
    • Careers
    • Partnerships
  • Contact Us
Menu
  • About
    • Overview
    • Management
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI® (naloxone)
  • Pipeline
    • Specialty Pharmaceuticals
    • APC-400 (tempol) – Capsule
  • Patients
  • Investors & Media
  • Careers
    • Careers
    • Partnerships
  • Contact Us

Category: ZIMHI

The Effects of Intramuscular Naloxone Dose on<br>Mu Receptor Displacement of Carfentanil in<br>Rhesus Monkeys

Time to Hit Opioids Early and Hard

Higher doses of naloxone are needed in the synthetic opioid era

An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 mL of intramuscular naloxone hydrochloride to 2 mg/0.4 mL intramuscular naloxone hydrochloride autoinjector in healthy subjects

Comparative Pharmacokinetic Analysis of Community Use Naloxone formulations for Acute Treatment of Opioid Overdose

Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level

Sign Up For Adamis Email Alerts

Choose Your Preferences
Adamis Pharmaceuticals logo - Click here to go back to the homepage

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.

Linkedin Twitter

COMPANY

  • About Us
  • Overview
  • Leadership
  • Board of Directors

PRODUCTS

  • SYMJEPI® (epinephrine)
  • ZIMHI® (naloxone)

PIPELINE

  • Specialty Pharmaceuticals
  • APC-400 (tempol) – Capsule

INVESTORS & MEDIA

  • Overview
  • News & Releases
  • Stock Information
  • SEC Filings
  • Events and Presentations
  • Corporate Governance
  • Email Alerts

CONNECT

  • Careers
  • Partnerships
  • Contact Us

© 2023 Copyright Adamis Pharmaceuticals Corporation

  • Terms and Conditions
  • Privacy Policy
  • Accessibility Statement